Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Nov;86(2):304–310. doi: 10.1111/j.1365-2249.1991.tb05814.x

Actinomycin D upregulates lipopolysaccharide induction of macrophage procoagulant expression and tumour necrosis factor-alpha production.

H R Wheeler 1, E J Rockett 1, I Clark 1, C L Geczy 1
PMCID: PMC1554142  PMID: 1934597

Abstract

The antitumour antibiotic actinomycin D (Act D) and the aminosugar D-galactosamine both enhance the sensitivity of animals to bacterial lipopolysaccharide (LPS). Lipopolysaccharide stimulates macrophage membrane-bound procoagulant activity (MPCA) and tumour necrosis factor-alpha (TNF-alpha) production in vitro. We investigated the effects of LPS combined with either Act D or D-galactosamine on procoagulant and TNF-alpha production in vitro. Actinomycin D directly induced procoagulant on the malignant monocytoid cell line WEHI 265, and synergized with LPS to enhance MPCA on both WEHI 265 cells and thioglycollate-induced peritoneal exudate macrophages. In the presence of Act D, exudate macrophages expressed procoagulant in response to concentrations of LPS 100,000-fold lower than normally required. Pulsing experiments demonstrated that LPS primed these cells within 4 h to respond to Act D, whereas 4 h priming with Act D inhibited subsequent procoagulant induction by LPS. Although its effects on TNF-alpha production were less intense, low levels of Act D more than doubled TNF-alpha produced by LPS-stimulated exudate macrophages. Procoagulant expression and TNF-alpha production were not always co-ordinately expressed; interferon-gamma (IFN-gamma) synergized with LPS to enhance both responses but when IFN-gamma was combined with Act D only procoagulant was upregulated. D-galactosamine failed to affect these macrophage responses. Results indicate different in vivo mechanisms of enhancement of LPS toxicity by these two agents.

Full text

PDF
304

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agarwal M. K., Berry L. J. Effect of actinomycin-D on RES and development of tolerance to endotoxin in mice. J Reticuloendothel Soc. 1968 Aug;5(4):353–367. [PubMed] [Google Scholar]
  2. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  3. Billiau A. Gamma-interferon: the match that lights the fire? Immunol Today. 1988 Feb;9(2):37–40. doi: 10.1016/0167-5699(88)91256-X. [DOI] [PubMed] [Google Scholar]
  4. Collart M. A., Belin D., Vassalli J. D., de Kossodo S., Vassalli P. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J Exp Med. 1986 Dec 1;164(6):2113–2118. doi: 10.1084/jem.164.6.2113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Decker K., Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol. 1974;(71):77–106. doi: 10.1007/BFb0027661. [DOI] [PubMed] [Google Scholar]
  6. Farram E., Geczy C. L., Moon D. K., Hopper K. The ability of lymphokine and lipopolysaccharide to induce procoagulant activity in mouse macrophage cell lines. J Immunol. 1983 Jun;130(6):2750–2756. [PubMed] [Google Scholar]
  7. Freudenberg M. A., Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun. 1988 May;56(5):1352–1357. doi: 10.1128/iai.56.5.1352-1357.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Freudenberg M. A., Keppler D., Galanos C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun. 1986 Mar;51(3):891–895. doi: 10.1128/iai.51.3.891-895.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Galanos C., Freudenberg M. A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939–5943. doi: 10.1073/pnas.76.11.5939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Geczy C. L., Farram E., Moon D. K., Meyer P. A., McKenzie I. F. Macrophage procoagulant activity as a measure of cell-mediated immunity in the mouse. J Immunol. 1983 Jun;130(6):2743–2749. [PubMed] [Google Scholar]
  11. Geczy C. L., Jones A. Procoagulant induction by human lymphokine and interferon gamma/PMA on a myelomonocytic cell line, RC2a. Br J Haematol. 1988 Oct;70(2):211–218. doi: 10.1111/j.1365-2141.1988.tb02466.x. [DOI] [PubMed] [Google Scholar]
  12. Gregory S. A., Morrissey J. H., Edgington T. S. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol. 1989 Jun;9(6):2752–2755. doi: 10.1128/mcb.9.6.2752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hofmann F., Wagle S. R., Decker K. Effect of d-galactosamine administration on nucleotide and protein metabolism in isolated rat Kupffer cells. Hoppe Seylers Z Physiol Chem. 1976 Dec;357(10):1395–1400. doi: 10.1515/bchm2.1976.357.2.1395. [DOI] [PubMed] [Google Scholar]
  14. Kiener P. A., Marek F., Rodgers G., Lin P. F., Warr G., Desiderio J. Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol. 1988 Aug 1;141(3):870–874. [PubMed] [Google Scholar]
  15. Lyberg T. Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review. Haemostasis. 1984;14(5):430–439. doi: 10.1159/000215101. [DOI] [PubMed] [Google Scholar]
  16. Lyberg T., Ivhed I., Prydz H., Nilsson K. Thromboplastin as a marker for monocyte differentiation. Br J Haematol. 1983 Feb;53(2):327–335. doi: 10.1111/j.1365-2141.1983.tb02027.x. [DOI] [PubMed] [Google Scholar]
  17. Moon D. K., Geczy C. L. Recombinant IFN-gamma synergizes with lipopolysaccharide to induce macrophage membrane procoagulants. J Immunol. 1988 Sep 1;141(5):1536–1542. [PubMed] [Google Scholar]
  18. Moore K. L., Esmon C. T., Esmon N. L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989 Jan;73(1):159–165. [PubMed] [Google Scholar]
  19. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Niemetz J. Coagulant activity of leukocytes. Tissue factor activity. J Clin Invest. 1972 Feb;51(2):307–313. doi: 10.1172/JCI106815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pieroni R. E., Broderick E. J., Bundeally A., Levine L. A simple method for the quantitation of submicrogram amounts of bacterial endotoxin. Proc Soc Exp Biol Med. 1970 Mar;133(3):790–794. doi: 10.3181/00379727-133-34565. [DOI] [PubMed] [Google Scholar]
  22. Rapaport S. I., Hjort P. F. The blood clotting properties of rabbit peritoneal leukocytes in vitro. Thromb Diath Haemorrh. 1967 Feb 28;17(1-2):222–236. [PubMed] [Google Scholar]
  23. Remick D. G., Kunkel R. G., Larrick J. W., Kunkel S. L. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest. 1987 Jun;56(6):583–590. [PubMed] [Google Scholar]
  24. Rothstein J. L., Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A. 1988 Jan;85(2):607–611. doi: 10.1073/pnas.85.2.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ryan J., Geczy C. Coagulation and the expression of cell-mediated immunity. Immunol Cell Biol. 1987 Apr;65(Pt 2):127–139. doi: 10.1038/icb.1987.14. [DOI] [PubMed] [Google Scholar]
  26. Seckinger P., Zhang J. H., Hauptmann B., Dayer J. M. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5188–5192. doi: 10.1073/pnas.87.13.5188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shands J. W., Jr Macrophage procoagulants. Haemostasis. 1984;14(5):373–377. doi: 10.1159/000215094. [DOI] [PubMed] [Google Scholar]
  28. Sheehan K. C., Ruddle N. H., Schreiber R. D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol. 1989 Jun 1;142(11):3884–3893. [PubMed] [Google Scholar]
  29. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  30. Warr T. A., Rao L. V., Rapaport S. I. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood. 1990 Apr 1;75(7):1481–1489. [PubMed] [Google Scholar]
  31. Wheeler H. R., Geczy C. L. Induction of macrophage procoagulant expression by cisplatin, daunorubicin and doxorubicin. Int J Cancer. 1990 Oct 15;46(4):626–632. doi: 10.1002/ijc.2910460413. [DOI] [PubMed] [Google Scholar]
  32. Wijermans P. W., Rebel V. I., Ossenkoppele G. J., Huijgens P. C., Langenhuijsen M. M. Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of the bleeding disorder by cell differentiation. Blood. 1989 Feb 15;73(3):800–805. [PubMed] [Google Scholar]
  33. van Hinsbergh V. W., Kooistra T., van den Berg E. A., Princen H. M., Fiers W., Emeis J. J. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988 Nov;72(5):1467–1473. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES